Enevate's Next Generation Battery Technology Provides Lower Carbon Footprint During Electric Vehicle (EV) Manufacturing
Enevate, a pioneering battery innovation company featuring extreme fast charge and high energy density battery technologies for electric vehicles (EVs) and other markets, delivers up to 27 percent reduction of carbon dioxide (CO2) emissions for manufacturing of EV batteries with Enevate's XFC-EnergyTM technology compared to today's conventional lithium-ion EV batteries (21 percent for NCA and 27 percent for NMC cells [kg CO2 eq. cradle-to-gate, per 1 KWh cell capacity]).1 These accomplishments have the potential to lower an EV's carbon footprint at the start of life, which is significant because battery manufacturing is the highest contributor of CO2 emissions for the manufacturing of an EV.
Enevate utilizes a higher energy density material and an innovative, ultra-thin multi-layer design in its large format EV cells that meet the demanding EV specifications. Enevate's battery technology strives to provide EV and battery companies with a process for taking measurable, cost-effective steps toward meeting carbon reduction and carbon neutrality requirements. Enevate's goal is to foster widespread adoption of this technology and work to impact the environment positively.
With an estimated 28 million EVs sold per year by the middle of the decade, the automotive industry's role in electric vehicle greenhouse gas reduction has become an important one. To illustrate, a 21 percent greenhouse gas emissions reduction over conventional batteries manufactured in a 100 gigawatt-hour per year lithium-ion EV battery factory would be the equivalent of eliminating driving emissions annually from approximately 511,000 gasoline-only cars or not burning about 265 million gallons of gasoline each year. Please visit Enevate's Reduced CO2 Emissions webpage for more information.
"Enevate's core vision is to develop innovative battery technology that will enable a cleaner and more sustainable environment," said Enevate CEO Robert A. Rango. "By licensing our technology to automotive and battery manufacturers worldwide we hope to make this vision a reality by reducing the carbon footprint of EVs and making the world's environment better, cleaner and healthier."
"The CO2 emission reduction Enevate's battery technology offers is a very desirable contribution to Renault's aim to reach carbon neutrality in Europe by 2040 and worldwide by 2050. Furthermore, it provides another critical milestone to bring this battery technology to sustainable EV production by 2025," said Philippe Schulz, VP Advanced Powertrain Engineering - Groupe Renault.
As the global automotive industry accelerates to EVs and transitions from internal combustion engine vehicles, with growing concerns about sustainability and global warming, environmental impacts have become a central focus for automobile and battery manufacturers, consumers, environmental groups, and governments.
To that end, many companies, including Enevate, utilize a Life Cycle Analysis (LCA) tool to quantify a vehicle's environmental impact throughout its design life, including raw material extraction, manufacturing and assembly of the components, transportation to market, lifetime use, maintenance, and recycling. Enevate leverages its third-party verified, internationally standardized, multi-criteria LCA tool to calculate its battery technology's potential contribution to global warming due to carbon emissions and help our partners reach carbon neutrality.
Last year, Enevate announced its 4th generation XFC-EnergyTM technology, which is positioned to be a game-changer for the EV industry, providing a path to produce extreme fast-charge EV batteries at low cost and high-volume production. Enevate is currently working with multiple automotive OEMs and EV battery manufacturers to commercialize its technology for 2024-2025 model year EVs, utilizing existing manufacturing infrastructure with minimal investment required, a core goal of its development.
ABOUT ENEVATE (www.enevate.com)
Enevate develops and licenses advanced battery technology for electric vehicles (EVs), with a vision of EVs charging as fast as refueling gas cars, accessible and affordable to everyone, and accelerating EVs' mass adoption. With a portfolio of more than 400 patents issued and in process, Enevate's pioneering advancements (leveraging accelerated battery testing and machine learning) in silicon-dominant anodes and cells have resulted in battery technology that features five-minute extreme fast charging with high energy density, low-temperature operation for cold climates, low cost and safety advantages over conventional batteries.
Enevate's vision is to develop and propagate EV battery technology that contributes to a clean and sustainable environment. The Irvine, California-based company's investors include Renault-Nissan-Mitsubishi (Alliance Ventures), LG Chem, Samsung Venture Investment Corp, Fidelity Management & Research Company, Mission Ventures, Draper Fisher Jurvetson, Tsing Capital, Infinite Potential Technologies, Presidio Ventures – a Sumitomo Corporation company, Lenovo, CEC Capital, and Bangchak. Enevate®, the Enevate logo, HD-Energy®, and eBoost® are registered trademarks of Enevate Corporation.
1 Enevate CO2 emissions information in accordance with international standards ISO 14044:2006, section 6.1 critical review. Further information available from Enevate Corp., 101 Theory # 200, Irvine, CA 92617.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005318/en/
Contact information
Bill Blanning
media@enevate.com
714-916-4309
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 09:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approaches for combating cancer. IDEAL Japan follows the conclusion of the highly respected JCA (Japanese Cancer Association) Mauvernay Award in Japan, which honored Japanese scientists over the last 20 years, from 2004 through 2024. Debiopharm is now transitioning its historic award into the IDEAL Japan initiative aiming to accelerate preclinical scientific research that could give rise to new treatments for cancer patients. “Our vision is to collaborate to find a cure for cancer,”explained Thierry Mauvernay, President of Debiopharm. “We believe that our ongoing Swiss-Japanese connection needs to evolve and catalyze the trans
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 08:00:00 EET | Press release
Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117345890/en/ Adam Plich, Founder and CEO of Avanzanite. The announcement follows a record-breaking Q3 2025 for Avanzanite, with revenue tripling year-on-year and climbing over 20% quarter-on-quarter. This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio. Avanzanite was built to solve Europe’s rare-disease medicines access gap. Under one pan-European operation, Avanzanite brings toget
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 05:35:00 EET | Press release
Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through its partners by the end of October 2025, marking a threefold increase compared to the same period in 2024, with MSMEs among the key segments driving this growth. International Finance Corporation estimates a US$8 trillion financing gap for MSMEs in emerging markets and developing economies. With global platforms, from e-commerce to food delivery, entering emerging markets and local platforms in these markets continue to scale, many are looking to offer tailored credit services to better support MSMEs operating on their ecosystems. Doin
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 05:00:00 EET | Press release
Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in real-time global treasury management. It has already supported a successful H
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo ™ 300mg18.11.2025 04:51:00 EET | Press release
The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These improvements may contribute to an enhanced treatment journey for patients by helping reduce the disease burden they face throughout their care. Given its distinctive product profile, Omlyclo™ 300mg has the potential to become an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
